Evidence map›Paper›PMID 35845265›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2022

The iterative process of fluid biomarker development and validation in Alzheimer's disease.

Barbara B Bendlin, Henrik Zetterberg

Abstract readEditorial
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Barbara B BendlinCenter for Health Disparities Research University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA.
Henrik ZetterbergUK Dementia Research Institute at UCL London UK.

Funding

The Neighborhoods Study: Contextual Disadvantage and Alzheimer’s Disease and Related Dementias (ADRD)R01AG070883 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI AMY J. KIND · 2021 to 2026
$42.1M
Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI AMY J. KIND · 2019 to 2026
$34.5M
White matter degeneration: biomarkers in preclinical Alzheimer's DiseaseR01AG037639 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA · 2012 to 2023
$5.3M
SV2A PET imaging in Alzheimer's DiseaseR01AG062285 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA, CHRISTIAN, BRADLEY T · 2018 to 2022
$5.3M
Gut barrier function in Alzheimer's DiseaseR01AG070973 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA, REY, FEDERICO E · 2021 to 2025
$3.9M
Neighborhood Socioeconomic Contextual Disadvantage and Alzheimer's DiseaseRF1AG057784 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA, KIND, AMY J. · 2017 to 2017
$3.8M
Algebraic Formulations for Characterizing Structural Brain Connectivity Changes and Pathology Transmission Networks in Preclinical Alzheimer's DiseaseRF1AG059312 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA, SINGH, VIKAS · 2019 to 2019
$1.8M
NIA NIH HHS P30 AG062715NIA NIH HHS R01 AG037639NIA NIH HHS R01 AG062285NIA NIH HHS R01 AG070883NIA NIH HHS R01 AG070973NIA NIH HHS RF1 AG057784NIA NIH HHS RF1 AG059312
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35845265
PMCPMC9274795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.